Search

Your search keyword '"Neill DR"' showing total 53 results

Search Constraints

Start Over You searched for: Author "Neill DR" Remove constraint Author: "Neill DR"
53 results on '"Neill DR"'

Search Results

2. Emerging strategies to target virulence in Pseudomonas aeruginosa respiratory infections.

3. Galleria mellonella as an Antimicrobial Screening Model.

4. Secondary messenger signalling influences Pseudomonas aeruginosa adaptation to sinus and lung environments.

5. Airway metabolic profiling during Streptococcus pneumoniae infection identifies branched chain amino acids as signatures of upper airway colonisation.

6. Identification of two distinct phylogenomic lineages and model strains for the understudied cystic fibrosis lung pathogen Burkholderia multivorans .

7. Sulfur-Polymer Nanoparticles: Preparation and Antibacterial Activity.

8. An innate pathogen sensing strategy involving ubiquitination of bacterial surface proteins.

9. TNFR2 + regulatory T cells protect against bacteremic pneumococcal pneumonia by suppressing IL-17A-producing γδ T cells in the lung.

10. Influence of Streptococcus pneumoniae Within-Strain Population Diversity on Virulence and Pathogenesis.

11. Challenges and opportunities in the development of novel antimicrobial therapeutics for cystic fibrosis.

12. Pseudomonas aeruginosa utilizes the host-derived polyamine spermidine to facilitate antimicrobial tolerance.

13. Mechanistic Insights into the Impact of Air Pollution on Pneumococcal Pathogenesis and Transmission.

14. Development of liquid culture media mimicking the conditions of sinuses and lungs in cystic fibrosis and health.

15. Investigating the viability of sulfur polymers for the fabrication of photoactive, antimicrobial, water repellent coatings.

16. Antibacterial Activity of Inverse Vulcanized Polymers.

17. Pneumococcal Colonization and Virulence Factors Identified Via Experimental Evolution in Infection Models.

18. The Building Blocks of Antimicrobial Resistance in Pseudomonas aeruginosa : Implications for Current Resistance-Breaking Therapies.

19. Intestinal helminth co-infection is an unrecognised risk factor for increased pneumococcal carriage density and invasive disease.

20. Lower Density and Shorter Duration of Nasopharyngeal Carriage by Pneumococcal Serotype 1 (ST217) May Explain Its Increased Invasiveness over Other Serotypes.

21. Structural insights into loss of function of a pore forming toxin and its role in pneumococcal adaptation to an intracellular lifestyle.

22. Influenza-like illness is associated with high pneumococcal carriage density in Malawian children.

23. Increased pathogenicity of pneumococcal serotype 1 is driven by rapid autolysis and release of pneumolysin.

24. Exposure to diesel exhaust particles increases susceptibility to invasive pneumococcal disease.

25. Genome mining identifies cepacin as a plant-protective metabolite of the biopesticidal bacterium Burkholderia ambifaria.

26. Pneumolysin binds to the mannose receptor C type 1 (MRC-1) leading to anti-inflammatory responses and enhanced pneumococcal survival.

27. Evolutionary trade-offs associated with loss of PmrB function in host-adapted Pseudomonas aeruginosa.

28. E-cigarette vapour enhances pneumococcal adherence to airway epithelial cells.

29. Origins and evolution of innate lymphoid cells: Wardens of barrier immunity.

30. Innate lymphoid cells and parasites: Ancient foes with shared history.

31. Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa .

32. Airborne dust and high temperatures are risk factors for invasive bacterial disease.

33. Ca²⁺-dependent repair of pneumolysin pores: A new paradigm for host cellular defense against bacterial pore-forming toxins.

34. Circulating Pneumolysin Is a Potent Inducer of Cardiac Injury during Pneumococcal Infection.

35. Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice.

36. Pseudomonas aeruginosa adaptation in the nasopharyngeal reservoir leads to migration and persistence in the lungs.

37. A new protective role for S100A9 in regulation of neutrophil recruitment during invasive pneumococcal pneumonia.

38. The B lymphocyte differentiation factor (BAFF) is expressed in the airways of children with CF and in lungs of mice infected with Pseudomonas aeruginosa.

39. Density and duration of pneumococcal carriage is maintained by transforming growth factor β1 and T regulatory cells.

40. The pneumococcal polysaccharide capsule and pneumolysin differentially affect CXCL8 and IL-6 release from cells of the upper and lower respiratory tract.

41. IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction.

42. Nasopharyngeal carriage with Streptococcus pneumoniae augments the immunizing effect of pneumolysin toxoid B.

43. Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults.

44. Spir2; a novel QTL on chromosome 4 contributes to susceptibility to pneumococcal infection in mice.

45. Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13.

46. Transcription factor RORα is critical for nuocyte development.

47. T regulatory cells control susceptibility to invasive pneumococcal pneumonia in mice.

48. Novel immunogenic peptides elicit systemic anaphylaxis in mice: implications for peptide vaccines.

49. Nuocytes and beyond: new insights into helminth expulsion.

50. Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4.

Catalog

Books, media, physical & digital resources